<DOC>
	<DOCNO>NCT01084655</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 1/2 study TAK-700 combination docetaxel prednisone evaluate safety pharmacokinetics ( PK ) combination allow estimation prostate-specific antigen ( PSA ) response men metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>Study TAK-700 Combination With Docetaxel Prednisone Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion : Voluntary write consent Male patient 18 year old Estimated life expectancy 6 month Histologically cytologically confirm diagnosis prostate adenocarcinoma Radiographdocumented metastatic disease Progressive disease Prior surgical castration concurrent use agent medical castration Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Physical examination finding consistent study entry exclusion criterion identify exclude chronic condition Even surgically sterilize , patient must Practice effective barrier contraception entire study treatment period 6 month last dose study drug , OR Abstain heterosexual intercourse Any use opiate must stable least 2 week prior study entry Meet screen laboratory value specify protocol Suitable venous access Patients meeting follow exclusion criterion enrol study : Known hypersensitivity TAK700 , docetaxel , prednisone related compound Received follow within 30 day prior first dose TAK700 : prior therapy investigational compound ; prior herbal product know decrease PSA ; OR radiation therapy prostate cancer Received prior therapy TAK700 , aminoglutethimide , ketoconazole abiraterone ( Phase 1 , patient previously treat ketoconazole abiraterone eligible treatment ketoconazole abiraterone discontinue least 30 day prior enrollment ) Received antiandrogen therapy within 4 week flutamide 6 week others prior first dose study drug Received prior chemotherapy prostate cancer Current spinal cord compression , bilateral hydronephrosis neck outlet obstruction Symptoms investigator deems related prostate cancer Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Uncontrolled cardiovascular condition New York Heart Association Class ( NYHA ) Class III IV Uncontrolled hypertension despite medical therapy Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Unwilling unable comply protocol Major surgery serious infection within 14 day first dose TAK700 Lifethreatening illness unrelated cancer Uncontrolled nausea , vomit diarrhea Known gastrointestinal disease procedure could interfere oral absorption tolerance TAK700</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>